All News
🌟PSA vs RA 🌟
-UK cohort
PSA associated with:
👉⬆️ duration symptoms prior 2 referral
👉⬆️ interval between GP presentation and DX
👉⬇️DMARD commencement
👉⬇️ improvement in Dx activity @ 3/12
# We need to do better
#ACR22 Abst#1613 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
There is an association between the severity of skin and joint or axial disease, both at baseline and longitudinally, in pts presenting w/in 12 months of diagnosis of PsA. Abs 1511 #ACR22 @RheumNow https://t.co/PcVn6dITqU https://t.co/qxn3LBOW8d
Dr. Rachel Tate uptoTate ( View Tweet)
Even a 6 month delay in PsA diagnosis can lead to worse PROs on quality of life!
Likelihood of depression increased
Pts with PsA dx in <6 months reported better outcomes
Abs#1507 @RheumNow #ACR22 https://t.co/igCiH22CWi
Robert B Chao, MD doctorRBC ( View Tweet)
GUS (compared to RIS) uniquely binds both CD64+ myeloid cells and IL-23. CD64+ mononuclear phagocytes are enriched in the psoriatic skin and serve as the dominant IL-23 source. Does this lead to a change in clinical response? Abs 1487 #ACR22 @RheumNow https://t.co/P512bxSxRn
Dr. Rachel Tate uptoTate ( View Tweet)
‼️FAP (fibroblast activation protein)
PET-CT in PsA‼️
⚡️synovial and entheseal accum in PsA v HC
⚡️correlation of uptake with pain scores
⚡️IL-17A ⬇️ FAP, with arrest joint damage
⚡️persistent FAP - ⬆️ prog joint damage
❓new T2T in PsA❓
#ACR22 @RheumNow Abst#1602
Patricia Harkins DrTrishHarkins ( View Tweet)
How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves?
Survey shows <50% rheum collaborate with derm
Need updated EMRs and additional education
Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS
Robert B Chao, MD doctorRBC ( View Tweet)
⚡️PRESTO⚡️
📈PsA prediction tool in psoriasis
Risk of PsA at 1yr ⬆️:
👉younger
👉male
👉FHx Psoriasis
👉back stiffness
👉stiffness level
👉nail pitting
👉biologic use
👉⬆️ pain and global health
(AUC 72.3,95%CI 65.5,79.1)
#ACR22 @RheumNow Abst#1612
Patricia Harkins DrTrishHarkins ( View Tweet)
Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal antibodies and increased w/ ETN and SECU. Abs 1159 #ACR22 @RheumNow https://t.co/BtHMQ6apNI https://t.co/uZEYVQdiOU
Dr. Rachel Tate uptoTate ( View Tweet)
Ab1486 #ACR22
@Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA
Prediction base model w only traditional CV risks excellent (AUC 85.5)
Expanded model w damaged jts did not improve risk discrimination
@Rheumnow https://t.co/DMlOreW9zK
Eric Dein ericdeinmd ( View Tweet)
Ab1508 #ACR22 Enthesitis on PET/CT
20 untreated PsA pts w/ total body PET/CT
All 20 (100%) pts had entheseal inflammation
127/543 (~1/4) entheses showed inflammation
@RheumNow https://t.co/OQCBWW70bt
Eric Dein ericdeinmd ( View Tweet)
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow
Abstract #L02
💊Phase 3, randomized, placebo-controlled study
💉Biologic naive patients
✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi)
📍benefits sustained to week 52
🛑No new safety signals
Catherine Sims, MD DrCassySims ( View Tweet)
FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR
Dr. Rachel Tate uptoTate ( View Tweet)
Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs
Contrasting w/ data from real world TNF
Interesting data but small sample size & events N
https://t.co/gv8uvcThMD
Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg
Aurelie Najm AurelieRheumo ( View Tweet)
DANBIO registry: 1600+ pts RA, AxSpA, PsA
Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111)
Maintenance at 1yr:
>80%
> withdrawal in original IFX naive, but higher BL DA
Do second time switchers do better because of past switch experience?
Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz
Aurelie Najm AurelieRheumo ( View Tweet)
@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX
Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA.
Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity.
@RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
The greater the PsAID score, the more likely escalation in PsA treatment. Noted significant correlation between PsAID and physician global scores. Do you use PsAID in your clinic? Abs 1028 #ACR22 @RheumNow https://t.co/gcjm2XgPE3 https://t.co/bKPtXz5Nw8
Dr. Rachel Tate uptoTate ( View Tweet)
Do patients with PsA like online wellness programs? #ACR22 @RheumNow
🌈 186 patients, 86% women, 90% White
🌈sleep and nutrition were highly rated for wellness
🌈cost and fatigue barriers to adopting wellness behaviors
🌈 27% were open to an online wellness program
Catherine Sims, MD DrCassySims ( View Tweet)
BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w
Dr. Rachel Tate uptoTate ( View Tweet)
In clinic US guided entheseal biopsy? Abs 1025 at #ACR22 recommends the lateral epicondyle tendon plate in PsA pts. @RheumNow https://t.co/VomyFkecLq
Dr. Rachel Tate uptoTate ( View Tweet)
